Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells

Wang,Limengmeng; Xiao,Haowen; Zhang,Xing; Liao,Weichao; Fu,Shan; Huang,He

doi:10.3892/ijo.2015.3163

Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells

Authors:
- Limengmeng Wang
- Haowen Xiao
- Xing Zhang
- Weichao Liao
- Shan Fu
- He Huang
View Affiliations

Affiliations: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China
Published online on: September 14, 2015 https://doi.org/10.3892/ijo.2015.3163
Pages: 1685-1695
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

All-trans retinoic acid (ATRA) is one of the first line agents in differentiation therapy for acute promyelocytic leukemia (APL). However, drug resistance is a major problem influencing the efficacy of ATRA. Identification of mechanisms of ATRA resistance are urgenly needed. In the present study, we found that expression of C/EBPα, an important transcription factor for myeloid differentiation, was significantly suppressed in ATRA resistant APL cell line NB4-R1 compared with ATRA sensitive NB4 cells. Moreover, two forms of C/EBPα were unequally suppressed in NB4-R1 cells. Suppression of the full-length form P42 was more pronounced than the truncated form P30. Inhibition of PI3K/Akt/mTOR pathway was also observed in NB4-R1 cells. Moreover, C/EBPα expression was reduced by PI3K inhibitor LY294002 and mTOR inhibitor RAD001 in NB4 cells, suggesting that inactivation of the PI3K/Akt/mTOR pathway was responsible for C/EBPα suppression in APL cells. We restored C/EBPα P42 and P30 by lentivirus vectors in NB4-R1 cells, respectively, and found C/EBPα P42, but not P30, could increase CD11b, CD14, G-CSFR and GM-CSFR expression, which indicated the occurrence of myeloid differentiation. Further upregulating of CD11b expression and differential morphological changes were found in NB4-R1 cells with restored C/EBPα P42 after ATRA treatment. However, CD11b expression and differential morphological changes could not be induced by ATRA in NB4-R1 cells infected with P30 expressing or control vector. Thus, we inferred that ATRA sensitivity of NB4-R1 cells was enhanced by restoration of C/EBPα P42. In addition, we used histone deacetylase inhibitor trichostatin (TSA) to restore C/EBPα expression in NB4-R1 cells. Similar enhancement of myeloid differentiation and cell growth arrest were detected. Together, the present study demonstrated that suppression of C/EBPα P42 induced by PI3K/Akt/mTOR inhibition impaired the differentiation and ATRA sensitivity of APL cells. Restoring C/EBPα P42 is an attractive approach for differentiation therapy in ATRA resistant APL.

View Figures

View References

1	Rowley JD: Mapping of human chromosomal regions related to neoplasia: Evidence from chromosomes 1 and 17. Proc Natl Acad Sci USA. 74:5729–5733. 1977. View Article : Google Scholar : PubMed/NCBI
2	de Thé H, Chomienne C, Lanotte M, Degos L and Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558–561. 1990. View Article : Google Scholar : PubMed/NCBI
3	de Thé H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A: The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:675–684. 1991. View Article : Google Scholar : PubMed/NCBI
4	Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, et al: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 391:815–818. 1998. View Article : Google Scholar : PubMed/NCBI
5	Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Viré E, Nomdedeu JF, Jenuwein T, Pelicci PG, Minucci S, et al: Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell. 11:513–525. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, Jin W, Jia X, Luo R, Tan Y, Zhu X, Yang X, Wang X and Wang K: Transcriptional repression of CDKN2D by PML/RARα contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells. Cell Death Dis. 5:e14312014. View Article : Google Scholar
7	Bräuer-Hartmann D, Hartmann JU, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa MV, Pelicci PG, Müller-Tidow C, Tenen DG, Niederwieser D, et al: PML/RARα-regulated miR-181a/b cluster targets the tumor suppressor RASSF1A in acute promyelocytic leukemia. Cancer Res. 75:3411–3424. 2015. View Article : Google Scholar
8	Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, Castaigne S and Fenaux P: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 85:2643–2653. 1995.PubMed/NCBI
9	Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, et al: Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes. J Clin Oncol. 32:3406–3412. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tomita A, Kiyoi H and Naoe T: Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As₂O₃) in acute promyelocytic leukemia. Int J Hematol. 97:717–725. 2013. View Article : Google Scholar : PubMed/NCBI
11	Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R and Jonveaux P: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 8:1741–1749. 1999. View Article : Google Scholar : PubMed/NCBI
12	Ozpolat B, Mehta K, Tari AM and Lopez-Berestein G: All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol. 70:39–47. 2002. View Article : Google Scholar : PubMed/NCBI
13	Su M, Alonso S, Jones JW, Yu J, Kane MA, Jones RJ and Ghiaur G: All-trans retinoic acid activity in acute myeloid leukemia: Role of cytochrome P450 enzyme expression by the microenvironment. PLoS One. 10:e01277902015. View Article : Google Scholar : PubMed/NCBI
14	Zhou DC, Hallam SJ, Lee SJ, Klein RS, Wiernik PH, Tallman MS and Gallagher RE: Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells. Cancer Res. 58:5770–5776. 1998.PubMed/NCBI
15	Côté S, Zhou D, Bianchini A, Nervi C, Gallagher RE and Miller WH Jr: Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood. 96:3200–3208. 2000.PubMed/NCBI
16	Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, et al: Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 120:2098–2108. 2012. View Article : Google Scholar : PubMed/NCBI
17	Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
18	Ge DZ, Sheng Y and Cai X: Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines. Sci Rep. 4:48212014. View Article : Google Scholar : PubMed/NCBI
19	Liu T, Men Q, Wu G, Yu C, Huang Z, Liu X and Li W: Tetrandrine induces autophagy and differentiation by activating ROS and Notch1 signaling in leukemia cells. Oncotarget. 6:7992–8006. 2015. View Article : Google Scholar : PubMed/NCBI
20	Liu L, Liu L, Leung LH, Cooney AJ, Chen C, Rosengart TK, Ma Y and Yang J: Knockdown of SALL4 protein enhances all-trans retinoic acid-induced cellular differentiation in acute myeloid leukemia cells. J Biol Chem. 290:10599–10609. 2015. View Article : Google Scholar : PubMed/NCBI
21	Heo SK, Noh EK, Yoon DJ, Jo JC, Koh S, Baek JH, Park JH, Min YJ and Kim H: Rosmarinic acid potentiates ATRA-induced macrophage differentiation in acute promyelocytic leukemia NB4 cells. Eur J Pharmacol. 747:36–44. 2015. View Article : Google Scholar
22	Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF and Keller JR: C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood. 107:4308–4316. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, et al: Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 21:853–863. 2004. View Article : Google Scholar : PubMed/NCBI
24	McClellan JS, Dove C, Gentles AJ, Ryan CE and Majeti R: Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc Natl Acad Sci USA. 112:4074–4079. 2015. View Article : Google Scholar : PubMed/NCBI
25	Pabst T and Mueller BU: Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 15:5303–5307. 2009. View Article : Google Scholar : PubMed/NCBI
26	Lin FT, MacDougald OA, Diehl AM and Lane MDA: A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: Transcriptional activator lacking antimitotic activity. Proc Natl Acad Sci USA. 90:9606–9610. 1993. View Article : Google Scholar : PubMed/NCBI
27	Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W and Tenen DG: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 27:263–270. 2001. View Article : Google Scholar : PubMed/NCBI
28	Kuo YY, Hou HA, Chen YK, Li LY, Chen PH, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, et al: The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica. 99:1799–1807. 2014. View Article : Google Scholar : PubMed/NCBI
29	Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z, Bohlander SK, Ryo A, Tenen DG and Behre G: Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. Leukemia. 24:914–923. 2010. View Article : Google Scholar : PubMed/NCBI
30	Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, et al: Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood. 121:159–169. 2013. View Article : Google Scholar :
31	Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, Morlando M, Bozzoni I and Fatica A: C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 6:18534–18544. 2015. View Article : Google Scholar : PubMed/NCBI
32	Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, et al: CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 110:3695–3705. 2007. View Article : Google Scholar : PubMed/NCBI
33	Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME and Hiebert SW: The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol. 18:322–333. 1998.PubMed/NCBI
34	Cilloni D, Carturan S, Gottardi E, Messa F, Messa E, Fava M, Diverio D, Guerrasio A, Lo-Coco F and Saglio G: Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. Blood. 102:2705–2706. 2003. View Article : Google Scholar : PubMed/NCBI
35	Santana-Lemos BA, de Lima Lange AP, de Lira Benício MT, José TD, Lucena-Araújo AR, Krause A, Thomé CH and Rego EM: The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica. 96:617–620. 2011. View Article : Google Scholar :
36	Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, Jotterand M, Meyer-Monard S, Fey MF and Pabst T: CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood. 106:1369–1375. 2005. View Article : Google Scholar : PubMed/NCBI
37	Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, et al: A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature. 500:93–97. 2013. View Article : Google Scholar : PubMed/NCBI
38	McIvor Z, Hein S, Fiegler H, Schroeder T, Stocking C, Just U and Cross M: Transient expression of PU.1 commits multipotent progenitors to a myeloid fate whereas continued expression favors macrophage over granulocyte differentiation. Exp Hematol. 31:39–47. 2003. View Article : Google Scholar : PubMed/NCBI
39	Dahl R and Simon MC: The importance of PU.1 concentration in hematopoietic lineage commitment and maturation. Blood Cells Mol Dis. 31:229–233. 2003. View Article : Google Scholar : PubMed/NCBI
40	Iriyama N, Yuan B, Yoshino Y, Hatta Y, Horikoshi A, Aizawa S, Takei M, Takeuchi J, Takagi N and Toyoda H: Enhancement of differentiation induction and upregulation of CCAAT/enhancer-binding proteins and PU.1 in NB4 cells treated with combination of ATRA and valproic acid. Int J Oncol. 44:865–873. 2014.PubMed/NCBI
41	Friedman AD, Keefer JR, Kummalue T, Liu H, Wang QF and Cleaves R: Regulation of granulocyte and monocyte differentiation by CCAAT/enhancer binding protein alpha. Blood Cells Mol Dis. 31:338–341. 2003. View Article : Google Scholar : PubMed/NCBI
42	Spiekermann K, Bagrintseva K, Schwab R, Schmieja K and Hiddemann W: Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 9:2140–2150. 2003.PubMed/NCBI
43	Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, et al: FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 103:267–274. 2004. View Article : Google Scholar